Differing associations between Aβ accumulation, hypoperfusion, blood–brain barrier dysfunction and loss of PDGFRB pericyte marker in the precuneus and parietal white matter in Alzheimer's disease

Journal of Cerebral Blood Flow and Metabolism

Volumn 38, Issue 1, 2018, Pages 103-115

  Miners, J Scott ^a   Schulz, Isabel ^a   Love, Seth ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Alzheimer's disease; blood brain barrier; cerebral hypoperfusion; fibrinogen; pericyte

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; FIBRINOGEN; HEMOGLOBIN; MYELIN AND LYMPHOCYTE PROTEIN; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RECOMBINANT PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CAPILLARY DENSITY; CAPILLARY LEAK SYNDROME; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; PERICYTE; PRECUNEUS; PRIORITY JOURNAL; TISSUE OXYGENATION; VASCULAR AMYLOIDOSIS; WHITE MATTER; BIOSYNTHESIS; BRAIN; BRAIN CIRCULATION; CAPILLARY PERMEABILITY; FEMALE; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; MALE; PERICYTES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; WHITE MATTER;

EID: 85039851085     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X17690761     Document Type: Article

References (59)

1. Baloyannis SJ, Baloyannis IS. The vascular factor in Alzheimer's disease: A study in Golgi technique and electron microscopy. J Neurol Sci 2012; 322: 117–121.
2. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001; 64: 575–611.
3. Halliday MR, Rege SV, Ma Q, Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J Cereb Blood Flow Metab 2016; 36: 216–227.
4. Sengillo JD, Winkler EA, Walker CT, Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease. Brain Pathol 2013; 23: 303–310.
5. Cortes-Canteli M, Mattei L, Richards AT, Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration. Neurobiol Aging 2015; 36: 608–617.
6. Hultman K, Strickland S, Norris EH. The APOE ∈4/∈4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients. J Cereb Blood Flow Metab 2013; 33: 1251–1258.
7. Zipser BD, Johanson CE, Gonzalez L, Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2007; 28: 977–986.
8. Craggs LJL, Fenwick R, Oakley AE, Immunolocalization of platelet-derived growth factor receptor-β (PDGFR-β) and pericytes in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Neuropath Appl Neuro 2015; 41: 557–570.
9. Bell RD, Winkler EA, Sagare AP, Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010; 68: 409–427.
10. Asllani I, Habeck C, Scarmeas N, Multivariate and univariate analysis of continuous arterial spin labeling perfusion MRI in Alzheimer's disease. J Cereb Blood Flow Metab 2008; 28: 725–736.
11. Benzinger TLS, Blazey T, Jack CR, Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A 2013; 110: E4502–E4509.
12. Binnewijzend MAA, Kuijer JPA, Benedictus MR, Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: A marker for disease severity. Radiology 2013; 267: 221–230.
13. Dai WY, Lopez OL, Carmichael OT, Mild cognitive impairment and Alzheimer disease: Patterns of altered cerebral blood flow at MR imaging. Radiology 2009; 250: 856–866.
14. Langbaum JBS, Chen KW, Caselli RJ, Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E ∈4 allele. Arch Neurol 2010; 67: 462–468.
15. Matsuda H. Cerebral blood flow and metabolic abnormalities in Alzheimer's disease. Ann Nucl Med 2001; 15: 85–92.
16. Sakamoto S, Ishii K, Sasaki M, Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease. J Neurol Sci 2002; 200: 27–32.
17. Ruitenberg A, den Heijer T, Bakker SLM, Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam study. Ann Neurol 2005; 57: 789–794.
18. Niwa K, Kazama K, Younkin L, Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol 2002; 283: H315–H323.
19. Niwa K, Kazama K, Younkin SG, Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 2002; 9: 61–68.
20. Niwa K, Porter VA, Kazama K, Aβ-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 2001; 281: H2417–2424.
21. Chui HC, Zheng L, Reed BR, Vascular risk factors and Alzheimer's disease: Are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimers Research & Therapy 2012; 4: 1.
22. Love S, Miners JS. Cerebrovascular disease in ageing and Alzheimer's disease. Acta Neuropathol 2016; 131: 645–658.
23. Miners JS, Palmer JC, Tayler H, Abeta degradation or cerebral perfusion? Divergent effects of multifunctional enzymes. Front Aging Neurosci 2014; 6: 238.
24. Barker R, Ashby EL, Wellington D, Pathophysiology of white matter perfusion in Alzheimer's disease and vascular dementia. Brain 2014; 137: 1524–1532.
25. Barker R, Wellington D, Esiri MM, Assessing white matter ischemic damage in dementia patients by measurement of myelin proteins. J Cereb Blood Flow Metab 2013; 33: 1050–1057.
26. Miners JS, Palmer JC, Love S. Pathophysiology of hypoperfusion of the precuneus in early Alzheimer's disease. Brain Pathol 2016; 26: 533–541.
27. Thomas TL, Miners SJ, Kehoe PG, Correlation between levels of VEGF and insoluble Aβ(1-42) in the cerebral cortex in Alzheimer's disease. Neuropathol Appl Neurobiol 2015; 41: 22.
28. Love S, Miners JS. White matter hypoperfusion and damage in dementia: Post-mortem assessment. Brain Pathol 2015; 25: 99–107.
29. Palmer JC, Barker R, Kehoe PG, Endothelin-1 is elevated in Alzheimer's disease and upregulated by amyloid-β. J Alzheimers Dis 2012; 29: 853–861.
30. Palmer JC, Baig S, Kehoe PG, Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Aβ. Am J Pathol 2009; 175: 262–270.
31. Wu Z, Guo H, Chow N, Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med 2005; 11: 959–965.
32. Winkler EA, Bell RD, Zlokovic BV. Pericyte-specific expression of PDGF β receptor in mouse models with normal and deficient PDGF beta receptor signaling. Mol Neurodegener 2010; 5: 32.
33. Sagare AP, Bell RD, Zhao Z, Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun 2013, pp. 4.
34. Montagne A, Barnes SR, Sweeney MD, Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015; 85: 296–302.
35. Sagare AP, Sweeney MD, Makshanoff J, Shedding of soluble platelet-derived growth factor receptor-β from human brain pericytes. Neurosci Lett 2015; 607: 97–101.
36. van de Haar HJ, Burgmans S, Jansen JF, Blood-brain barrier leakage in patients with early Alzheimer disease. Radiology 2016; 281: 527–535.
37. van de Haar HJ, Jansen JF, van Osch MJ, Neurovascular unit impairment in early Alzheimer's disease measured with magnetic resonance imaging. Neurobiol Aging 2016; 45: 190–196.
38. Garrigue P, Giacomino L, Bucci C, Single photon emission computed tomography imaging of cerebral blood flow, blood-brain barrier disruption, and apoptosis time course after focal cerebral ischemia in rats. Int J Stroke 2016; 11: 117–126.
39. Lorberboym M, Lampl Y, Sadeh M. Correlation of 99mTc-DTPA SPECT of the blood-brain barrier with neurologic outcome after acute stroke. J Nucl Med 2003; 44: 1898–1904.
40. Montine TJ, Phelps CH, Beach TG, National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012; 123: 1–11.
41. Miners JS, Clarke P, Love S. Clusterin levels are increased in Alzheimer's disease and influence the regional distribution of Aβ. Brain Pathol. 2016. Epub ahead of print 8 July 2016. DOI: 10.1111/bpa.12392.
42. Chalmers K, Wilcock GK, Love S. APOE ∈4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of Aβ protein. Neuropathol Appl Neurobiol 2003; 29: 231–238.
43. Olichney JM, Hansen LA, Galasko D, The apolipoprotein E ∈4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology 1996; 47: 190–196.
44. Craggs LJ, Fenwick R, Oakley AE, Immunolocalization of platelet-derived growth factor receptor-β (PDGFR-β) and pericytes in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Neuropathol Appl Neurobiol 2015; 41: 557–570.
45. Miners S, Moulding H, de Silva R, Reduced vascular endothelial growth factor and capillary density in the occipital cortex in dementia with Lewy bodies. Brain Pathol 2014; 24: 334–343.
46. Verbeek MM, Van Nostrand WE, Otte-Holler I, Amyloid-β-induced degeneration of human brain pericytes is dependent on the apolipoprotein E genotype. Ann N Y Acad Sci 2000; 903: 187–199.
47. Love S, Miners JS. Cerebral hypoperfusion and the energy deficit in Alzheimer's disease. Brain Pathol 2016; 26: 607–617.
48. Masliah E, Mallory M, Alford M, PDGF is associated with neuronal and glial alterations of Alzheimer's disease. Neurobiol Aging 1995; 16: 549–556.
49. Yang SP, Bae DG, Kang HJ, Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging 2004; 25: 283–290.
50. Hagedorn M, Balke M, Schmidt A, VEGF coordinates interaction of pericytes and endothelial cells during vasculogenesis and experimental angiogenesis. Dev Dynam 2004; 230: 23–33.
51. Greenberg JI, Shields DJ, Barillas SG, A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008; 456: 809–813.
52. Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro-Oncology 2005; 7: 452–464.
53. Bai Y, Zhu XJ, Chao J, Pericytes contribute to the disruption of the cerebral endothelial barrier via increasing VEGF expression: Implications for stroke. Plos One 2015; 10: e0124362.
54. Patel NS, Mathura VS, Bachmeier C, Alzheimer's beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2. J Neurochem 2010; 112: 66–76.
55. Charidimou A, Pantoni L, Love S. The concept of sporadic cerebral small vessel disease: A road map on key definitions and current concepts. Int J Stroke 2016; 11: 6–18.
56. Ashby EL, Love S, Kehoe PG. Assessment of activation of the plasma Kallikrein-Kinin system in frontal and temporal cortex in Alzheimer's disease and vascular dementia. Neurobiol Aging 2012; 33: 1345–1355.
57. Bartus RT, Elliott P, Hayward N, Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: Evidence for a sensitive, auto-regulated, receptor-mediated system. Immunopharmacology 1996; 33: 270–278.
58. Bartus RT, Elliott PJ, Dean RL, Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol 1996; 142: 14–28.
59. Raymond JJ, Robertson DM, Dinsdale HB. Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier. Can J Neurol Sci 1986; 13: 214–220.